Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Peptide Vaccination (APVAC) in Newly Diagnosed Glioblastoma
NCT02149225Phase 1Completed
- Sponsor
- Immatics
- Start
- Oct 2014
- Primary completion
- Jun 2018
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of APVAC in glioblastoma (GBM), sponsored by Immatics. Primary endpoints: Safety and tolerability profile, Feasibility of APVAC processes and 1 more. Started Oct 2014; status: completed.
02
Drugs
APVAC
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02149225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02149225.